- Baudax Bio ( NASDAQ: BXRX ) added ~70% pre-market Tuesday after announcing a positive outcome in its first interim analysis for Phase 2 trial for experimental neuromuscular blocking agent BX1000 in patients undergoing elective surgery.
- The trial is designed to evaluate the neuromuscular blockade of BX1000 in 80 adults undergoing elective surgery utilizing total intravenous anesthesia.
- Its pre-planned first interim analysis was focused on evaluating the intubating conditions for each patient after BX1000 use in a 20-patient group.
- Baudax ( BXRX ) said that all patients in the group reached the criteria for Good or Excellent intubating conditions at 60 seconds. The study drug was well tolerated, with no severe or serious adverse events.
- The company intends to continue the study as planned and expects to report topline results in April after completing enrollment in Q1 2023.
For further details see:
Baudax Bio jumps 70% after Phase 2 success for neuromuscular blocking agent